The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD to Trade on the NASDAQ Global Select Market

Tuesday, January 03, 2012

ARIAD to Trade on the NASDAQ Global Select Market07:35 EST Tuesday, January 03, 2012 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Company has been upgraded to trade on the NASDAQ Global Select Market, the top listing tier for NASDAQ companies with the highest initial listing standards of any exchange in the world based on financial and liquidity requirements. Shares of ARIAD common stock will begin trading on the NASDAQ Global Select Market effective today. “We are honored to be added to the NASDAQ Global Select Market as we advance our mission of becoming a leader in the discovery, development and global commercialization of breakthrough cancer medicines,” stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. ARIAD was previously listed on the NASDAQ Global Market. ARIAD's shares will be transferred to the Global Select Market at the opening of business today, January 3, 2012, and will continue to be traded under the ticker ARIA. About ARIAD ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD's approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. Forward-looking StatementsCertain of the statements made in this press release may be forward looking. Actual results or developments may differ materially from those projected or implied in these forward looking statements. You should not place undue reliance on these forward looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to ARIAD and our business can be found under the heading "Risk Factors" in the filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. ARIAD Pharmaceuticals, Inc.For InvestorsMaria E. Cantor, 617-621-2208Maria.cantor@ariad.comorFor MediaLiza Heapes, 617-621-2315Liza.heapes@ariad.com